The cumulative sales revenue of the anti-amyloid \u03b2 protofibril antibody \u201cLeqembi\u00ae\u201d for fiscal year 2025 was JPY 88 billion, with JPY 44.6 billion in the U.S., JPY 24.4 billion in Japan, and JPY 12.4 billion in China.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4523-20260430-01.pdf","jir_short_summary":"The cumulative sales revenue of the anti-amyloid \u03b2 protofibril antibody \u201cLeqembi\u00ae\u201d for fiscal year 2025 was JPY 88 billion, with JPY 44.6 billion in the U.S., JPY 24.4 billion in Japan, and JPY 12.4 billion in China.","jir_summary":"### Overview of Sales Revenue\nEisai Co., Ltd. announced preliminary cumulative sales revenue for the anti-amyloid \u03b2 protofibril antibody \u201cLeqembi\u00ae\u201d (generic name: lecanemab) for fiscal year 2025 (April 1, 2025, to March 31, 2026). Global total sales reached JPY 88 billion, with major country breakdowns of JPY 44.6 billion in the U.S., JPY 24.4 billion in Japan, and JPY 12.4 billion in China. These figures are preliminary and unaudited.\n\n### Future Disclosure Plans and Business Framework\nDetailed sales revenue information and fiscal year 2025 performance will be disclosed at the financial results announcement scheduled for May 15, 2026. Eisai leads the global development and regulatory submission of lecanemab, with Eisai and Biogen jointly managing commercialization and promotion.","jir_financial_highlights":"Sales Revenue (Leqembi\u00ae): JPY 88 billion (Unknown)\nSales Revenue (U.S.): JPY 44.6 billion (Unknown)\nSales Revenue (Japan): JPY 24.4 billion (Unknown)\nSales Revenue (China): JPY 12.4 billion (Unknown)","jir_category":"","jir_hashtags":"#EisaiCoLtd, #sales_update, #JapaneseStocks","jir_key_figures":"Leqembi\u00ae cumulative sales revenue for fiscal year 2025: JPY 88 billion (unaudited preliminary figures)\nU.S. sales revenue: JPY 44.6 billion\nJapan sales revenue: JPY 24.4 billion","jir_meta_title":"[Eisai] Leqembi\u00ae Sales Reach JPY 88 Billion in FY2025 | April 2026 Preliminary Report","jir_meta_description":"Eisai Co., Ltd. announced preliminary cumulative sales revenue of JPY 88 billion for the anti-amyloid \u03b2 protofibril antibody \u201cLeqembi\u00ae\u201d in fiscal year 2025, with breakdowns of JPY 44.6 billion in the U.S., JPY 24.4 billion in Japan, and JPY 12.4 billion in China.","jir_og_title":"[Eisai] Leqembi\u00ae Sales Reach JPY 88 Billion in FY2025 | April 2026 Preliminary Report","jir_og_description":"Eisai's anti-amyloid \u03b2 antibody \u201cLeqembi\u00ae\u201d recorded sales revenue of JPY 88 billion in fiscal year 2025. Sales by major countries are also disclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"sales_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-43931","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n